Trials / Completed
CompletedNCT00616460
ACRIPAB- Trial: Anti Coagulation Regimen In High Risk PAtients for Bleeding
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- HaEmek Medical Center, Israel · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine the safety/efficacy of Bivallirudin Vs unfractionated heparin (UFH) on top of dual antiplatelet therapy in patients with high tendency for bleeding during urgent and elective PCI.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bivalirudin | Bivalirudin: loading dose 0.75mg/kg bolus During procedure: 1.75mg/kg/hour. UFH: loading dose 60 Units /kg During procedure: keeping ACT \< 250 |
Timeline
- Start date
- 2008-02-01
- Primary completion
- 2011-10-01
- Completion
- 2011-10-01
- First posted
- 2008-02-15
- Last updated
- 2015-06-12
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT00616460. Inclusion in this directory is not an endorsement.